|Ra Pharmaceuticals Initiates Dosing in Phase 1b Pharmacokinetic Study Evaluating RA101495 SC in Patients with Renal Impairment|
“Building on the clinical data collected to date from which we observed the favorable PK and pharmacodynamic (PD) profile of RA101495, this Phase 1b trial is designed to evaluate RA101495 in a subset of patients with renal impairment, with the aim of expanding the range of indications for RA101495 as a potential therapy for patients with complement-mediated disorders,” said Ramin Farzaneh-Far, MD, Chief Medical Officer of Ra Pharma. “C5 is a clinically-validated target for multiple complement-mediated renal disorders, including aHUS, and this trial is designed to provide the necessary PK data to support the future evaluation of RA101495 in renal disorders.”
The Phase 1b, multi-center, open-label trial is designed to evaluate the PK profile of RA101495 SC in patients with renal impairment. The trial is planned to enroll approximately 16 subjects, including eight patients with severe renal impairment matched with eight healthy control subjects with normal renal function. Each patient will receive a single, SC dose of 0.3 mg/kg of RA101495. The trial will compare the PK profile in patients with renal impairment with subjects with normal renal function.
“The initiation of dosing in this Phase 1b trial is a meaningful step
for advancing RA101495 in multiple complement-mediated renal
About RA101495 SC
Ra Pharma is developing RA101495 SC for paroxysmal nocturnal hemoglobinuria (PNH), generalized myasthenia gravis (gMG), atypical hemolytic uremic syndrome (aHUS), and lupus nephritis (LN). The product is designed for convenient, once-daily, subcutaneous (SC) self-administration. RA101495 SC is a synthetic, macrocyclic peptide discovered using Ra Pharma’s powerful proprietary drug discovery technology. The peptide binds complement component 5 (C5) with sub-nanomolar affinity and allosterically inhibits its cleavage into C5a and C5b upon activation of the classical, alternative, or lectin pathways. By binding to a region of C5 corresponding to C5b, RA101495 SC also disrupts the interaction between C5b and C6 and prevents assembly of the membrane attack complex (MAC). This activity defines an additional, novel mechanism for the inhibition of C5 function. To learn more about RA101495 SC, please visit: http://rapharma.com/pipeline/ra101495/.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the therapeutic potential and regulatory and clinical progress of our product candidates, including RA101495, the potential for RA101495 to address additional indications, and the Phase 1b PK clinical trial evaluating RA101495 in patients with renal impairment, including statements regarding trial design and enrollment. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risks that Ra Pharma’s product candidates, including RA101495, will not successfully be developed or commercialized; the risk of delay in enrollment or release of topline results from that expected, including with respect to the Phase 1b PK clinical trial; the risk that initial data from the Company’s global Phase 2 clinical program evaluating RA101495 for the treatment of PNH may not be indicative of final study results; the risk that initial data from a limited number of patients may not be indicative of results from the full patient enrollment planned for such study; as well as the other factors discussed in the “Risk Factors” section in Ra Pharma’s most recently filed Annual Report on Form 10-K, as well as other risks detailed in Ra Pharma’s subsequent filings with the Securities and Exchange Commission. There can be no assurance that the actual results or developments anticipated by Ra Pharma will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Ra Pharma. All information in this press release is as of the date of the release, and Ra Pharma undertakes no duty to update this information unless required by law.